Last reviewed · How we verify
LY2875358 at Part A highest dose
At a glance
| Generic name | LY2875358 at Part A highest dose |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Modality | Small molecule |
|---|
| Phase | Phase 1 |
|---|
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.